News | May 08, 2024
WACKER expands production capacity for biopharmaceuticals in San Diego
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Subscribe To Our Newsletter & Stay Updated
